Does the media refer more to NTLA or BEAM?

In the previous week, Intellia Therapeutics had 1 more articles in the media than Beam Therapeutics. MarketBeat recorded 5 mentions for Intellia Therapeutics and 4 mentions for Beam Therapeutics. Intellia Therapeutics' average media sentiment score of 1.21 beat Beam Therapeutics' score of 1.16 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NTLA or CRSP?

In the previous week, Intellia Therapeutics and Intellia Therapeutics both had 5 articles in the media. Intellia Therapeutics' average media sentiment score of 1.21 beat CRISPR Therapeutics' score of -0.08 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer EDIT or NTLA?

In the previous week, Editas Medicine and Editas Medicine both had 5 articles in the media. Intellia Therapeutics' average media sentiment score of 1.21 beat Editas Medicine's score of 0.69 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer COGT or NTLA?

In the previous week, Cogent Biosciences had 14 more articles in the media than Intellia Therapeutics. MarketBeat recorded 19 mentions for Cogent Biosciences and 5 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.21 beat Cogent Biosciences' score of 0.79 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MIRM or NTLA?

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than Intellia Therapeutics. MarketBeat recorded 9 mentions for Mirum Pharmaceuticals and 5 mentions for Intellia Therapeutics. Mirum Pharmaceuticals' average media sentiment score of 1.23 beat Intellia Therapeutics' score of 1.21 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Intellia Therapeutics (NTLA) Competitors

$12.56 -0.28 (-2.18%)

Closing price 04:00 PM Eastern

Extended Trading

$12.57 +0.01 (+0.08%)

As of 05:29 PM Eastern

Compare

NTLA vs. BEAM, CRSP, EDIT, COGT, and MIRM

Should you buy Intellia Therapeutics stock or one of its competitors? Intellia Therapeutics's main competitors and comparable companies include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Cogent Biosciences (COGT), and Mirum Pharmaceuticals (MIRM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Intellia Therapeutics compare to Beam Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Intellia Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market.

In the previous week, Intellia Therapeutics had 1 more articles in the media than Beam Therapeutics. MarketBeat recorded 5 mentions for Intellia Therapeutics and 4 mentions for Beam Therapeutics. Intellia Therapeutics' average media sentiment score of 1.21 beat Beam Therapeutics' score of 1.16 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Intellia Therapeutics currently has a consensus price target of $21.15, indicating a potential upside of 68.41%. Beam Therapeutics has a consensus price target of $49.00, indicating a potential upside of 72.96%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Beam Therapeutics has a net margin of -54.75% compared to Intellia Therapeutics' net margin of -672.16%. Beam Therapeutics' return on equity of -30.71% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$59.51M	29.58	-$412.69M	-$3.36	N/A
Beam Therapeutics	$156.04M	18.75	-$79.99M	-$0.86	N/A

Summary

Beam Therapeutics beats Intellia Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Intellia Therapeutics compare to CRISPR Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by company insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Intellia Therapeutics and Intellia Therapeutics both had 5 articles in the media. Intellia Therapeutics' average media sentiment score of 1.21 beat CRISPR Therapeutics' score of -0.08 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Intellia Therapeutics has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$59.51M	29.58	-$412.69M	-$3.36	N/A
CRISPR Therapeutics	$3.51M	1,572.38	-$581.60M	-$4.76	N/A

Intellia Therapeutics has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market.

Intellia Therapeutics presently has a consensus target price of $21.15, indicating a potential upside of 68.41%. CRISPR Therapeutics has a consensus target price of $68.06, indicating a potential upside of 19.23%. Given Intellia Therapeutics' higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

Intellia Therapeutics has a net margin of -672.16% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-672.16%	-57.79%	-47.29%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

Summary

Intellia Therapeutics beats CRISPR Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Intellia Therapeutics compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Editas Medicine has higher earnings, but lower revenue than Intellia Therapeutics. Editas Medicine is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	11.37	-$160.06M	-$0.75	N/A
Intellia Therapeutics	$59.51M	29.58	-$412.69M	-$3.36	N/A

Editas Medicine presently has a consensus price target of $5.50, indicating a potential upside of 83.33%. Intellia Therapeutics has a consensus price target of $21.15, indicating a potential upside of 68.41%. Given Editas Medicine's stronger consensus rating and higher possible upside, equities research analysts plainly believe Editas Medicine is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35

In the previous week, Editas Medicine and Editas Medicine both had 5 articles in the media. Intellia Therapeutics' average media sentiment score of 1.21 beat Editas Medicine's score of 0.69 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Editas Medicine has a net margin of -157.32% compared to Intellia Therapeutics' net margin of -672.16%. Intellia Therapeutics' return on equity of -57.79% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-157.32%	-196.63%	-38.17%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

Editas Medicine has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market.

Summary

Intellia Therapeutics beats Editas Medicine on 9 of the 16 factors compared between the two stocks.

How does Intellia Therapeutics compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Intellia Therapeutics (NASDAQ:NTLA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

88.8% of Intellia Therapeutics shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cogent Biosciences has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -672.16%. Intellia Therapeutics' return on equity of -57.79% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-84.47%	-47.72%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

Cogent Biosciences currently has a consensus price target of $49.40, indicating a potential upside of 36.35%. Intellia Therapeutics has a consensus price target of $21.15, indicating a potential upside of 68.41%. Given Intellia Therapeutics' higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35

Cogent Biosciences has higher earnings, but lower revenue than Intellia Therapeutics. Cogent Biosciences is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A
Intellia Therapeutics	$59.51M	29.58	-$412.69M	-$3.36	N/A

Cogent Biosciences has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market.

In the previous week, Cogent Biosciences had 14 more articles in the media than Intellia Therapeutics. MarketBeat recorded 19 mentions for Cogent Biosciences and 5 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.21 beat Cogent Biosciences' score of 0.79 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Intellia Therapeutics beats Cogent Biosciences on 9 of the 16 factors compared between the two stocks.

How does Intellia Therapeutics compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Intellia Therapeutics (NASDAQ:NTLA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Mirum Pharmaceuticals currently has a consensus price target of $137.33, indicating a potential upside of 41.99%. Intellia Therapeutics has a consensus price target of $21.15, indicating a potential upside of 68.41%. Given Intellia Therapeutics' higher possible upside, analysts plainly believe Intellia Therapeutics is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35

88.8% of Intellia Therapeutics shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Mirum Pharmaceuticals has a net margin of -139.18% compared to Intellia Therapeutics' net margin of -672.16%. Mirum Pharmaceuticals' return on equity of -36.28% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

Mirum Pharmaceuticals has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than Intellia Therapeutics. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$618.07M	10.16	-$23.36M	-$14.55	N/A
Intellia Therapeutics	$59.51M	29.58	-$412.69M	-$3.36	N/A

In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than Intellia Therapeutics. MarketBeat recorded 9 mentions for Mirum Pharmaceuticals and 5 mentions for Intellia Therapeutics. Mirum Pharmaceuticals' average media sentiment score of 1.23 beat Intellia Therapeutics' score of 1.21 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mirum Pharmaceuticals beats Intellia Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Intellia Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NTLA vs. The Competition

Export

Metric	Intellia Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.76B	$3.99B	$7.29B	$12.71B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-3.74	11.78	271.39	24.10
Price / Sales	29.58	1,299.82	604.58	77.05
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	2.17	17.27	11.18	6.40
Net Income	-$412.69M	-$22.72M	$3.46B	$348.28M
7 Day Performance	3.89%	2.91%	1.98%	0.92%
1 Month Performance	17.05%	9.75%	7.32%	5.10%
1 Year Performance	19.39%	54.82%	24.76%	16.16%

Intellia Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NTLA Intellia Therapeutics	3.236 of 5 stars	$12.56 -2.2%	$21.15 +68.4%	+22.1%	$1.76B	$59.51M	N/A	600	Positive News
BEAM Beam Therapeutics	2.1679 of 5 stars	$27.10 +1.3%	$49.00 +80.8%	+78.8%	$2.80B	$139.74M	N/A	510	Positive News
CRSP CRISPR Therapeutics	2.6129 of 5 stars	$54.28 +1.4%	$68.06 +25.4%	+9.5%	$5.18B	$11M	N/A	460	Positive News
EDIT Editas Medicine	2.3731 of 5 stars	$2.84 +0.7%	$5.40 +90.1%	+11.1%	$436.17M	$47.01M	N/A	230
COGT Cogent Biosciences	2.6853 of 5 stars	$37.87 -0.2%	$49.40 +30.4%	+203.1%	$6.57B	N/A	N/A	80	Positive News Analyst Upgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NTLA) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intellia Therapeutics (NTLA) Competitors

NTLA vs. BEAM, CRSP, EDIT, COGT, and MIRM

How does Intellia Therapeutics compare to Beam Therapeutics?

Summary

How does Intellia Therapeutics compare to CRISPR Therapeutics?

Summary

How does Intellia Therapeutics compare to Editas Medicine?

Summary

How does Intellia Therapeutics compare to Cogent Biosciences?

Summary

How does Intellia Therapeutics compare to Mirum Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTLA vs. The Competition

Intellia Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intellia Therapeutics (NTLA) Competitors

NTLA vs. BEAM, CRSP, EDIT, COGT, and MIRM

How does Intellia Therapeutics compare to Beam Therapeutics?

Which has more volatility and risk, NTLA or BEAM?

Does the media refer more to NTLA or BEAM?

Do analysts rate NTLA or BEAM?

Do institutionals & insiders have more ownership in NTLA or BEAM?

Is NTLA or BEAM more profitable?

Which has better earnings and valuation, NTLA or BEAM?

Summary

How does Intellia Therapeutics compare to CRISPR Therapeutics?

Do institutionals and insiders have more ownership in NTLA or CRSP?

Does the media refer more to NTLA or CRSP?

Which has higher valuation and earnings, NTLA or CRSP?

Which has more risk & volatility, NTLA or CRSP?

Do analysts rate NTLA or CRSP?

Is NTLA or CRSP more profitable?

Summary

How does Intellia Therapeutics compare to Editas Medicine?

Which has stronger valuation and earnings, EDIT or NTLA?

Do analysts prefer EDIT or NTLA?

Does the media prefer EDIT or NTLA?

Do insiders and institutionals have more ownership in EDIT or NTLA?

Is EDIT or NTLA more profitable?

Which has more volatility and risk, EDIT or NTLA?

Summary

How does Intellia Therapeutics compare to Cogent Biosciences?

Do insiders and institutionals have more ownership in COGT or NTLA?

Is COGT or NTLA more profitable?

Do analysts recommend COGT or NTLA?

Which has better valuation and earnings, COGT or NTLA?

Which has more risk & volatility, COGT or NTLA?

Does the media prefer COGT or NTLA?

Summary

How does Intellia Therapeutics compare to Mirum Pharmaceuticals?

Do analysts recommend MIRM or NTLA?

Do institutionals & insiders have more ownership in MIRM or NTLA?

Is MIRM or NTLA more profitable?

Which has more volatility & risk, MIRM or NTLA?

Which has higher earnings & valuation, MIRM or NTLA?

Does the media prefer MIRM or NTLA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTLA vs. The Competition

Intellia Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools